Monica Amendolara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Monica Amendolara has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Portacci
Institute of Respiratory Disease, Department of Translational Biomedicine and neuroscience, University “Aldo Moro”, Bari, Italy, Bari, Italy
4 shared publications - Giovanna Elisiana Carpagnano
Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University “Aldo Moro”, 70121 Bari, Italy
4 shared publications - Silvano Dragonieri
Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University “Aldo Moro”, 70121 Bari, Italy
4 shared publications - Vitaliano Nicola Quaranta
Department of Respiratory Diseases, University of Bari, 70121 Bari, Italy
4 shared publications - Ilaria Iorillo
Respiratory Diseases, University of Bari, 70121 Bari, Italy
3 shared publications - Sara Quaranta
Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University “Aldo Moro”, 70124 Bari, Italy
2 shared publications
Latest Publications
- Open Access
- 9 April 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (2) , 1-9
The impact of PAP therapy first impression on short-term treatment adherence
Purpose: Positive airway pressure (PAP) treatment for obstructive sleep apnea syndrome (OSAS) is often burdened by lower adherence rates. Patients’ perception and acceptance of PAP therapy play a crucial role in achieving acceptable adherence. Method: We conducted a prospective cohort study to assess patients’ initial impressions of PAP therapy using a six-item questionnaire. The questionnaire evaluated CPAP tolerance, interface comfort, titration pressure, likelihood of CPAP use, expected health benefits, and overall attitude toward PAP therapy. Patients underwent a baseline awake PAP therapy trial (T0) followed by titration with an automatic device (APAP). After one month of titration, a fixed CPAP value was set (T1). Follow-ups occurred at 1 (T2), 3 (T3), and 6 (T4) months after the start of treatment. Adherence to PAP therapy was considered sufficient if the mean device usage was ≥ 4 h/night at T4. Results: After six months, 77% of the enrolled patients achieved high PAP treatment adherence. Questionnaire scores generally improved from T0 to T4, particularly in CPAP tolerance, likelihood of treatment adherence, expected health benefits, and overall judgment of PAP therapy. Time-to-event analysis revealed that higher baseline scores in titration pressure comfort, likelihood of CPAP adherence, and overall judgment of PAP therapy were significantly associated with higher adherence likelihood. Conclusion: Patients’ first judgement on PAP therapy could significantly influence short-term adherence. Early identification and management of patients’ complaints and discomforts could improve adherence rates and PAP perception over time.
- 9 April 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (2) , 1-9
Open AccessThe impact of PAP therapy first impression on short-term treatment adherence
Purpose: Positive airway pressure (PAP) treatment for obstructive sleep apnea syndrome (OSAS) is often burdened by lower adherence rates. Patients’ perception and acceptance of PAP therapy play a crucial role in achieving acceptable adherence. Method: We conducted a prospective cohort study to assess patients’ initial impressions of PAP therapy using a six-item questionnaire. The questionnaire evaluated CPAP tolerance, interface comfort, titration pressure, likelihood of CPAP use, expected health benefits, and overall attitude toward PAP therapy. Patients underwent a baseline awake PAP therapy trial (T0) followed by titration with an automatic device (APAP). After one month of titration, a fixed CPAP value was set (T1). Follow-ups occurred at 1 (T2), 3 (T3), and 6 (T4) months after the start of treatment. Adherence to PAP therapy was considered sufficient if the mean device usage was ≥ 4 h/night at T4. Results: After six months, 77% of the enrolled patients achieved high PAP treatment adherence. Questionnaire scores generally improved from T0 to T4, particularly in CPAP tolerance, likelihood of treatment adherence, expected health benefits, and overall judgment of PAP therapy. Time-to-event analysis revealed that higher baseline scores in titration pressure comfort, likelihood of CPAP adherence, and overall judgment of PAP therapy were significantly associated with higher adherence likelihood. Conclusion: Patients’ first judgement on PAP therapy could significantly influence short-term adherence. Early identification and management of patients’ complaints and discomforts could improve adherence rates and PAP perception over time.
- 19 February 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 239, 108008
Diaphragm function in patients with asthma and healthy controls: A cross-sectional study
- 19 February 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 239, 108008
Diaphragm function in patients with asthma and healthy controls: A cross-sectional study
- Open Access
- 3 May 2024
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 46 (5) , 4271-4285
The Role of Galectins in Asthma Pathophysiology: A Comprehensive Review
Galectins are a group of β-galactoside-binding proteins with several roles in immune response, cellular adhesion, and inflammation development. Current evidence suggest that these proteins could play a crucial role in many respiratory diseases such as pulmonary fibrosis, lung cancer, and respiratory infections. From this standpoint, an increasing body of evidence have recognized galectins as potential biomarkers involved in several aspects of asthma pathophysiology. Among them, galectin-3 (Gal-3), galectin-9 (Gal-9), and galectin-10 (Gal-10) are the most extensively studied in human and animal asthma models. These galectins can affect T helper 2 (Th2) and non-Th2 inflammation, mucus production, airway responsiveness, and bronchial remodeling. Nevertheless, while higher Gal-3 and Gal-9 concentrations are associated with a stronger degree of Th-2 phlogosis, Gal-10, which forms Charcot–Leyden Crystals (CLCs), correlates with sputum eosinophilic count, interleukin-5 (IL-5) production, and immunoglobulin E (IgE) secretion. Finally, several galectins have shown potential in clinical response monitoring after inhaled corticosteroids (ICS) and biologic therapies, confirming their potential role as reliable biomarkers in patients with asthma.
- 3 May 2024
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 46 (5) , 4271-4285
Open AccessThe Role of Galectins in Asthma Pathophysiology: A Comprehensive Review
Galectins are a group of β-galactoside-binding proteins with several roles in immune response, cellular adhesion, and inflammation development. Current evidence suggest that these proteins could play a crucial role in many respiratory diseases such as pulmonary fibrosis, lung cancer, and respiratory infections. From this standpoint, an increasing body of evidence have recognized galectins as potential biomarkers involved in several aspects of asthma pathophysiology. Among them, galectin-3 (Gal-3), galectin-9 (Gal-9), and galectin-10 (Gal-10) are the most extensively studied in human and animal asthma models. These galectins can affect T helper 2 (Th2) and non-Th2 inflammation, mucus production, airway responsiveness, and bronchial remodeling. Nevertheless, while higher Gal-3 and Gal-9 concentrations are associated with a stronger degree of Th-2 phlogosis, Gal-10, which forms Charcot–Leyden Crystals (CLCs), correlates with sputum eosinophilic count, interleukin-5 (IL-5) production, and immunoglobulin E (IgE) secretion. Finally, several galectins have shown potential in clinical response monitoring after inhaled corticosteroids (ICS) and biologic therapies, confirming their potential role as reliable biomarkers in patients with asthma.
- 12 April 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 226, 107628
Can Galectin-3 be a reliable predictive biomarker for post-COVID syndrome development?
- 12 April 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 226, 107628
Can Galectin-3 be a reliable predictive biomarker for post-COVID syndrome development?